Tobacco Use Disorder

Clinical picture

• Smoking within 30 minutes of waking is the single best marker of dependence severity and reliably predicts difficulty quitting.
• Withdrawal starts within hours as irritability, anxiety, poor concentration, restlessness, increased appetite, and disrupted sleep.
• Most patients arrive having made multiple prior quit attempts and carry real demoralization about their capacity to succeed.
• Physical findings include chronic cough, reduced exercise tolerance, delayed wound healing, and accelerated skin and dental aging.
• Use is tightly cue-bound to coffee, driving, phone calls, alcohol, and work breaks rather than to blood nicotine level alone.
• Vaping and dual use are now common, so ask specifically about e-cigarette nicotine strength and pod or disposable device use.

Criteria snapshot

• Requires at least 2 of 11 criteria in 12 months, with DSM-5-TR using a single tobacco use disorder rather than an abuse and dependence split.
• Severity is mild 2-3, moderate 4-5, or severe 6 or more criteria, which maps loosely onto traditional nicotine dependence severity.
• Tobacco withdrawal requires 4 or more characteristic symptoms within 24 hours of abrupt cessation or reduction after daily use.
• Risky-use and social-impairment criteria discriminate less well than for other substances because tobacco is legal and rarely intoxicating.
• The Fagerstrom Test for Nicotine Dependence and time-to-first-cigarette usefully complement DSM criteria for treatment planning.

Neurobiology

• Nicotine agonizes alpha4beta2 nicotinic acetylcholine receptors on VTA neurons, releasing dopamine in the nucleus accumbens within seconds.
• Inhaled delivery reaches the brain in about 10 to 20 seconds, producing rapid, highly repeatable reinforcement thousands of times per year.
• Chronic exposure upregulates nicotinic receptors, and desensitization between cigarettes generates the withdrawal and craving cycle.
• CYP2A6 metabolism rate determines the nicotine metabolite ratio, which predicts relative response to varenicline versus the patch.
• CHRNA5-A3-B4 gene cluster variants raise heavy smoking and lung cancer risk independent of self-reported consumption levels.
• Combustion products rather than nicotine cause most harm, including cardiovascular disease, COPD, and cancers of many organ systems.

Psychology

• Massed conditioning pairs each cigarette with reinforcement hundreds of times monthly, creating exceptionally durable cue reactivity.
• Patients report smoking to relieve stress, but relief of withdrawal accounts for most of the perceived calming effect they describe.
• Weight gain concern, averaging about 4 to 5 kg after quitting, is a major barrier especially for women and should be addressed directly.
• Low self-efficacy after prior failed attempts predicts relapse, so reframe earlier quits as practice attempts yielding usable data.
• Smoking is embedded in social routine and identity, so replacing the ritual matters as much as replacing the nicotine itself.

Differential & comorbidity

• Prevalence is two to four times higher in schizophrenia, bipolar disorder, depressive disorders, and other substance use disorders.
• Smoking induces CYP1A2, so quitting can raise clozapine and olanzapine levels by 30% to 50% and requires prompt dose review.
• Cessation does not worsen psychiatric illness, and the EAGLES trial found no excess neuropsychiatric events with varenicline or bupropion.
• Screen for COPD and coronary disease, and check eligibility for low-dose CT lung cancer screening in adults with 20 pack-years.
• Co-occurring alcohol use disorder sharply raises relapse risk, and treating both conditions concurrently improves both outcomes.

Pharmacologic treatment

• Varenicline 1 mg BID started about one week before quit day is the most effective single agent; nausea and vivid dreams are common.
• Combination nicotine replacement pairing a 21 mg patch with as-needed gum or lozenge outperforms any single-form product.
• Bupropion SR 150 mg BID roughly doubles quit rates and blunts post-cessation weight gain, but avoid it with any seizure history.
• Varenicline plus the patch may exceed either alone, and extending treatment to 12 to 24 weeks meaningfully reduces late relapse.
• Cytisinicline and preloading strategies are emerging options, and EAGLES confirmed the neuropsychiatric safety of first-line agents.

Psychotherapy

• Combining medication with behavioral counseling produces the highest quit rates, and either component used alone is clearly inferior.
• The 5 A's framework of ask, advise, assess, assist, and arrange should be applied at essentially every clinical encounter.
• CBT and behavioral counseling of 4 or more sessions totaling over 90 minutes shows a clear and reproducible dose-response effect.
• Motivational interviewing helps patients who are not yet ready to quit and increases the likelihood of future quit attempts.
• Quitlines such as 1-800-QUIT-NOW and text-message programs deliver effective counseling at scale with proactive follow-up contact.

Adjunct options

• Reduce-to-quit works: patients unwilling to set a quit date still benefit from NRT-supported gradual reduction over several weeks.
• Recheck psychiatric medication levels after quitting, especially clozapine and olanzapine, and review caffeine intake as well.
• Address weight concerns with activity planning and realistic expectations rather than postponing the quit attempt indefinitely.
• Switching completely to e-cigarettes reduces toxicant exposure relative to smoking but is not FDA-approved cessation therapy.
• Track exhaled carbon monoxide and schedule contact within the first week, when the large majority of lapses actually occur.

Clinical pearls

• Time to first cigarette under 30 minutes is the fastest measure of dependence.
• Quitting removes CYP1A2 induction: clozapine and olanzapine levels rise sharply.
• Combination NRT beats single-form NRT; do not settle for the patch alone.